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Abstract
Aims Cachexia, the wasting disorder associated with a wide
range of serious illnesses including cancer, is a major cause
of morbidity and mortality. There is currently no widely
approved therapeutic agent for treating or preventing
cancer-associated cachexia. Colorectal cancer and non-
small cell lung cancer have relatively high incidences of
cachexia, approximately 28% and 34%, respectively.
Neurohormonal overactivity has been implicated in the
genesis and progression of cachexia and beta receptor
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antagonism has been proposed as a potential therapy.
MT-102, a novel anabolic/catabolic transforming agent,
has a multi-functional effect upon three potential phar-
macological targets in cancer cachexia, namely reduced
catabolism through non-selective β-blockade, reduced
fatigue, and thermogenesis through central 5-HT1a
antagonism and increased anabolism through partial β-2
receptor agonism.
Methods At least 132 male and female patients, aged
between 25 and 80 years with a confirmed diagnosis of
late-stage non-small cell lung cancer or colorectal cancer,
with cachexia will be randomised to either one of the two
MT-102 doses or placebo in a 3:1:2 ratio (MT-102
10 mg BD−1/MT-102 2.5 mg BD/placebo). Patients will
continue on study treatment for maximally 16 weeks. The
primary endpoint, to be analysed by assigned treatment
group, will be body weight change over 16 weeks. For this
endpoint, the study has 85% power (0.05% significance
level) to detect per 4-week period a mean change of −0.8 kg
in the placebo group and 0 kg in the high-dose MT-102
arm. The first patient was randomised in February 2011 and
patient recruitment is expected to continue until mid-2012.
Perspective The ACT-ONE trial is designed to test whether
the anabolic/catabolic transforming agent MT-102 will
positively impact on the rate of change of body weight in
cancer cachexia, thereby evaluating a novel therapeutic
strategy in this hitherto poorly treatable condition. A
separate ACT-TWO trial will recruit patients who complete
the ACT-ONE trial and remain on randomised double-blind
medication. Participants in ACT-TWO will be followed for
an additional period with a separate primary endpoint.
Keywords Cancer . Cachexia . Intervention trial .
Functional capacity
1 Introduction
Cachexia, defined as weight loss, associated with a
chronic underlying disease, of at least 5% in 12 months
or less is associated with significant morbidity and
mortality [1]. Cachexia is known to accompany a wide
range of serious illnesses, including cancer, chronic heart
failure, COPD and chronic renal failure [2]. It is
associated with significant muscle wasting (myopenia
[3]), loss of muscle strength, fatigue [4] and anorexia [5],
in additional to neurohormonal and biochemical abnor-
malities [6]. Its pathophysiology is characterized by a
negative protein and energy balance driven by a variable
combination of reduced food intake and abnormal
metabolism.
Cachexia occurs in about a third of all cancer patients and
has been estimated to be the direct cause of death in 20% to
40% of all cancer-related deaths [2]. As for other solid
tumours, colorectal cancer (CRC) and non-small cell lung
cancer (NSCLC) have relatively high incidences of cachexia,
approximately 28% and 34%, respectively, and cachexia is
known to be associated with poor outcomes and increased
mortality in these cancers. Presently no therapy is widely
approved for the treatment of cancer-associated cachexia. It
would be very attractive to use relatively inexpensive non-
toxic, non-cytotoxic agents to treat cachexia in this patient
group.
MT-102 is an anabolic/catabolic transforming agent with
properties including non-specific beta-1 and beta-2 adren-
ergic receptor blocking activity and intrinsic sympathomi-
metic activity (ISA). In addition to its β-blocking and ISA
activity, MT-102 is a highly potent antagonist of 5-HT1a
receptors and binds to 5-HT 1a receptors in the brain. MT-
102 augments and decreases the time to onset of selective
serotonin reuptake inhibitor therapy via blockade of 5-HT1a
receptors. Through its combined pharmacological actions,
MT-102 has a multi-functional effect upon three potential
pharmacological targets, each of which is relevant for
cancer cachexia, as follows:
– Reduced catabolism, through non-selective β-blockade,
– Reduced fatigue and thermogenesis, through central 5-
HT1a antagonism,
– Increased anabolism, through partialβ2-receptor agonism,
This triad of pharmacological effects renders MT-102 a
unique and highly advantaged candidate for development in
cancer cachexia.
In the Yoshida hepatoma rat model, of cancer cachexia,
MT-102 demonstrates superior efficacy, relative to any
other agent tested, including other β-blockers [7]. In this
model, MT-102 administration leads to a dose-dependent
increase in weight, lean body mass and functional activity.
Furthermore, it has been shown to enhance the survival of
animals in this model in a dose-dependent manner. This
heightened efficacy is presumed to be due to the unique
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The ACT-ONE trial will assess the potential efficacy of
two different doses of MT-102 in patients with cachexia
due to two common forms of cancer. Data from this study,
along with that of the ACT-TWO study, will allow the
design and conduct of appropriate phase III clinical studies
to confirm the utility of MT-102 for this indication. The
ACT-ONE study is powered to establish an effect of the
higher dose of MT-102 upon the rate of change of body
weight; which is the cardinal factor in the definition of
cachexia, whereas the ACT-TWO study will be powered for
patients' clinical status. Both studies will also examine the
effect of MT-102 upon a number of measures of perfor-
mance and quality of life.
2 Methods
2.1 Study objectives
The primary objective of the ACT-ONE trial is to
investigate, compared to placebo, the effect of a 10 mg/BD
dose of MT-102 in comparison to placebo on the rate of
change of body weight over a 16-week period in patients
with cachexia related to underlying stages III and IV
colorectal or non-small cell lung cancer. Secondary objec-
tives will investigate, compared to placebo, the dose
response effects of two different doses of MT-102 in
comparison to placebo over a 16-week period on:
& the slope of weight change
& the short physical performance battery test(SPPB)
& the six-minute walk test (SMWT)
& hand grip strength (HGS)
& measures of quality of life (QOL)
& change of body composition according to dual energy
X-ray absorbitometry (DEXA)
& all cause mortality
& the adverse event profile
& inflammatory, neuroendocrine and catabolic/anabolic
biomarkers
2.2 Overall design and planning
The ACT-ONE trial is a multicentre, international rando-
mised, double-blind, placebo-controlled, dose-finding
phase II clinical study which will investigate patients with
cachexia related to non-small cell lung cancer or colorectal
cancer. It is planned to recruit 132 male or female patients
who will be treated with MT-102 or placebo for a period of
16 weeks. All patients will receive standard of care
chemotherapy, radiotherapy and supportive care throughout
the study at the discretion of their treating physician. The
physicians will be instructed to plan the chemotherapy
cycles and the functional assessment visits in such a manner
that chemotherapy does not interfere with the performance
of the functional assessments by the patients.
Potentially eligible patients will undergo screening
assessments which will include a set of performance
tests [stair climbing power (SCP), HGS, short physical
performance battery test and the SMWT]. In addition,
patients will be given a 7-day course of placebo tablets
(one tablet twice daily). Patients able to complete the
performance tests as required by the protocol selection
criteria and who are at least 80% compliant with the
placebo run-in phase will then be randomised to either
MT-102 2.5 or 10 mg BD or placebo. All patients will be
seen weekly for the first month after randomisation and
thereafter every 4 weeks, up to a maximum of 16 weeks.
The schedule of visits, examinations and investigations is
summarised in the study schematic shown in Fig. 1. The
dose of investigational product will be escalated by the
investigator in a blinded fashion. The maximum period of
drug titration is 4 weeks and the minimum is 2 weeks.
Patients will be required to attend study visits at 1-week
intervals after the start of the titration phase until
completion of dose escalation.
The study will be conducted in accordance with the
principles stated in the Declaration of Helsinki (1996),
International Conference on Harmonisation Good Clinical
Practice, and local and national regulations. Written
informed consent will be obtained for all patients prior to
any study-related procedures.
Visit Day
-8 -1 0 7 14 21 28 56 84 112 140
History and Consent x
Physical Exam x x x x
Vital Signs x x x x x x x x x x
ECG x x x x x x x x x x
Pregnancy Test x x
Start Placebo run-in x
Compliance Check x x x x x
Adverse Events x x x x x x x x x x x
Randomization x
Dose tolerability & Escalation** x x x x
Body Mass x x x x x x x x x x
Stair Climbing Power x x x x x x
Hand Grip Strength x x x x x x
Short Performance Battery x x x x x x
Six Minute Walk Test x x x x x x x
QOL x x x x x
DEXA Scan x x x
Safety Labs x x x x x x x x x x
Con Meds x x x x x x x x
Biomarkers x x x
Fig. 1 Study schematic
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2.3 Patient selection
The complete patient selection criteria are shown in Table 1.
Briefly, male and female patients aged between 25 and
80 years with a confirmed diagnosis of non-curative stage
III or IV CRC or NSCLC, not suitable for surgery and with
a life expectancy of at least 3 months will be potentially
eligible to participate in the ACT-ONE study if, in addition,
to the criteria listed in Table 1 they are suffering from
cachexia with ongoing weight loss that in the opinion of the
investigator is due to the underlying cancer.
2.4 Randomisation
It is planned that in total, 132 patients who comply with the
protocol selection criteria will be randomised in a 3:1:2
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Aged between 25 and 80 years of age and with a life expectancy
of greater than 3 months as judged by the treating physician
Age greater than 80 or less than 25 at baseline visit
Confirmed diagnosis of one of Previous history of administration of MT-102 or related products,
or any history of allergy or reaction to any component of the MT
102/study drug formulation
Non-curative stage III or stage IV CRC not suitable for surgery, or
Non-curative stage III or stage IV NSCLC not suitable for surgery;
Patients who are on first-line chemotherapy or those who have a
documented failure to respond or who have documented progression
following a first-line course of chemotherapy, with or without
radiotherapy, with one of the following regimes
Congestive heart failure or uncontrolled hypertension, pacemaker,
implantable defibrillator, or internalized metal stent, resting
pulse rate less than 68 bpm or high degree conduction defect;
resting supine SBP less than 100 mm Hg; or ≥20% weight loss
in the previous 3 Months or a body mass index (BMI) of less
than 16 kg/m2
For non-small cell lung cancer, a platinum-based regimen
For colorectal cancer, a 5FU or irinotecan-based regimen
Evidence of cachexia as judged by one of Current or planned treatment with any oral
≥5% documented weight loss in the previous 12 months Adrenal corticosteroids, beta-blockers, non-dihydropyridine calcium
antagonists, alpha adrenergic blockers, ivabradine, 5HT agonists or
antagonists, MAOI's, beta agonists, amiodarone,, megestrol,
anabolic steroids or any other prescription medication intended to
increase appetite or to treat unintentional weight loss
A subjective report of weight loss in the previous 12 months and
a recorded BMI less than 20.0 kg/m2
Ongoing documented weight loss of at least 1 kg in the week prior
to day 0; or 1.25 kg in the 2 weeks prior to day 0, or 1.5 kg in the
3 to 6 weeks prior to day 0; provided that BMI is not more than
25 kg/m2.
At least two of the following Any mechanical obstruction of the alimentary canal or any
history or evidence of intractable vomiting; or any physical,
medical, socioeconomic or other non-cancer-related cause for
simple starvation, muscle wasting or weight loss
Subjective report of decreased muscle strength
Subjective report of fatigue
Subjective report of anorexia
Abnormal biochemistry with one or more of the following
CRP>ULN (as per Central Lab normal value)
Anaemia (<12 g/dl)
Low serum albumin (<3.2 g/dl)
Patients of childbearing potential must use an effective method of
avoiding pregnancy (including oral, transdermal or implanted
contraceptives; an intrauterine device; male or female condoms;
diaphragm or cervical cap with spermicide; or abstinence) prior to
randomisation and must agree to continue using such precautions
until the end of the 140 day safety follow up
Scheduled to start any new course of chemotherapy or to undergo
a change in present chemotherapeutic regimen during the dose
escalation phase of the study (the first 3 weeks after randomisation);
any surgical procedure within the past month or any planned surgical
procedure
Willing and able to comply with the protocol and to complete the
study period;
Any clinical evidence of ascites or significant oedema or significant
pleural effusion at screening or baseline visit; A history of
bronchospasm and bronchial asthma; or a history or diagnosis
of brain metastases
ECOG performance status 0, 1 or 2 Receiving enteral tube feeding or
parenteral nutrition at screening or baseline visit
Able to complete the performance tests (SCP, SMWT, SPPB, HGS)
at the screening visit and with two consecutive pre-randomisation
SMWT results that differ by no more than 30% from each other
A history or clinical evidence of hyperthyroidism, cirrhosis, hepatic
failure, HIV, renal failure (as determined by a serum creatinine
>250 μmol/l or >2.83 mg/dl at screen) or active tuberculosis
At least 80% compliant during the placebo run-in period Pregnancy or lactation
Signed and dated informed consent, prior to receipt of any study
medication or any study related procedures.
Treatment with any investigational therapy within 28 days prior to the
screening visit
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ratio as follows: 66 patients will be randomised to receive
high-dose MT-102 (i.e. 10 mg/BD), 22 patients will be
randomised to receive low-dose MT-102 (i.e. 2.5 mg/BD),
and 44 patients will be randomised to receive placebo.
The first patient was randomised in February 2011
and patient recruitment is expected to continue until mid
2012.
2.5 Treatment regimens
MT-102 or placebo will be administered over a 16-week
period. The treatment regimens for the study are summar-
ised in Table 2.
3 Assessments
3.1 Functional evaluations
The SMWT will be conducted as described by Paul L.
Enright (Respiratory Care, August 2003 vol. 48 no. 8) [8].
The SCP test will be modified from that described by
Bean et al. (Arch Phys Med Rehabil vol. 88, May 2007)
[9] to account for the different stairway configurations at
the investigational sites. Results will be analysed as a
normalised power per kilogramme according to the
methods of Bean et al. [9]. An SPPB test will be
conducted as described by Guralnik et al. (Journal of
Gerontology 1994, vol. 49, no. 2) [10]. A HGS test will be
modified from that described by Bassey (1990; NIH,
1990) [11].
QoL will be assessed using the EQ-5D instrument on days
at days 0, 28, 56, 84 and 112. The EQ-5D questionnaire will
be administered by the investigator using the relevant
validated instrument and using the patient's preferred lan-
guage. The patient's answers will be recorded directly into
the CRF by the investigator. The patient will be asked to
complete the visual analogue scale section of the EQ-5D
directly on the CRF. DEXA scans will be performed at
selected DEXA scan centres on days at day −1, 56 and 112.
3.2 Biomarker studies
Samples from selected sites will be stored at −70° centigrade
and then analysed after completion of the study. A panel of
nutritional, inflammatory cardiovascular and neurohormonal
biomarkers will be conducted on these retained samples.
Depending upon the clinical outcomes observed in this study,
the constituents of this panel will be selected from: total
cholesterol, low-density lipoprotein, high-density lipoprotein,
triglycerides, pre-albumin, cortisol, high-sensitivity C-
reactive protein, interleukin-6, tumour necrosis factor (TNF),
soluble TNF-receptors, pro-calcitonin, adrenaline, nor-
adrenaline, aldosterone, cortisol, hehydroepiandrosterone,
free testosterone, matrix metalloproteinase-2,matrix
metalloproteinase-9, growth hormone, insulin-like growth
factor-1, leptin, allantoin, B-type natriuretic peptide (BNP),
N-terminal BNP, atrial natriuretic peptide (ANP), mid-region
pro-ANP, co-peptin, pro-adrenomedulin and s-pindolol. The
biomarker panel will be used to examine for potential
correlates of safety and efficacy for future clinical examination
and research.
3.3 Pharmaco-vigilance and safety assessments
As defined by the ICH Guideline for Good Clinical Practice
(CPMP/ICH/135/95), adverse events, serious adverse
events and serious unexpected suspected adverse reactions
will be captured and reported for this study. The ACT-ONE
Trial has appointed independent medical monitors (IMMs)
with experience in the conduct and review of multicentre
phase II or III oncology studies to review cumulative safety
surveillance data on a regular basis throughout the study
and make recommendations regarding further conduct of
the study. The IMMs will also review safety data judged to
be medically significant by the medical monitor. The IMMs
will review blinded safety surveillance data reported to the
sponsor, but may request to be unblinded if necessary to
make safety assessments and study recommendations
provided that no study or sponsor personnel shall be
unblinded in this process. The IMMs will make recom-
mendations to the sponsor to stop study entry and dosing if
they deem it necessary.
3.4 Sample size and statistical considerations
The underlying hypothesis for this trial is that high dose (i.e.
20 mg) of MT-102, relative to placebo, favourably affects the
Table 2 Treatment regimens
Group Patient no. Daily dose (mg) Day nos.a
A 22 5 0–6
5 7–13
5 14 onwards
B 66 5 0–6
10 7–13
20 14 onwards
C 44 0 0–6
0 7–13
0 14 onwards
a Patients that are unable to tolerate the dose escalation in any group
will be allowed to decrease their dose under the investigator's
supervision, without breaking the blind
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primary endpoint. Sample size calculations were therefore
based on:
– the null-hypothesis (Ho) that there is no difference in
the mean weight loss rate between high-dose MT-102
and placebo,
– a two-sided significance test for the rejection of Ho
with a level α of 0.05,
– a power of 85%,
– an expected mean weight change per 4-week period of
−0.8 kg in the placebo group and a mean weight
change per 4-week period of 0 kg in the high-dose MT-
102 arm,
– a standard deviation of 1.2 kg per 4-week period,
– an allocation ratio of 3:2:1, i.e. MT-102 10 mg BD/MT-
102 2.5 mg BD/placebo.
The size of the primary modified intention-to-treat
(mITT) analysis population for this trial has been set to
102 patients randomised in a 3:1:2 ratio (active high-dose
MT-102/active low-dose MT-102/placebo). To allow for
20% of recruited patients who do not comply with the
criteria for inclusion in the mITT population, 132 patients
in total will be started on study treatment (66 patients in the
active high dose, 22 patients in the active low dose and 44
patients in the placebo arm). The sample size considerations
for this study were based on the results of the Randomized
Clinical Trial of Adenosine 5-Triphosphate in Patients With
Advanced Non-Small-Cell Lung Cancer (Journal of the
National Cancer Institute, Vol. 92, No. 4, February 16,
2000) [12]. In this randomised trial, the weight loss rate in
patients allocated to adenosine 5-triphosphate was com-
pared to patients allocated to placebo. Patients included in
this trial had stage IIIb or IV NSCLC and were followed for
28 weeks with a weight assessment every 4 weeks. In the
placebo group, the mean weight change per 4-week period
was −1 kg (95% confidence interval [CI]=−1.5 to −0.5,
n=24). The corresponding standard deviation is 1.2 kg per
4-week period. In the same study, patients considered to
be cachexic (i.e., weight loss >5% of weight before illness)
had a mean weight loss rate of −1.6 kg per 4-week
period.
Based on the above assumptions, a mean weight change
per 4-week period of −0.8 kg in the placebo group versus
no weight loss in the high-dose-treated group will be used
for the MT-102 trial and a standard deviation of 1.2 kg per
4 weeks.
3.5 Statistical and analytical plan
Demographics and baseline characteristics will be docu-
mented by descriptive statistics on the ITT and modified
ITT populations. The safety analysis will be performed by
treatment received. The efficacy criteria will be displayed
by treatment arm, by dose and time point for the following
assessments:
– body weight and body weight changes;
– DEXA scan
– stair climbing power;
– six-minute walk test;
– short physical performance battery test;
– hand grip strength;
– EQ-5D QoL data.
The safety analyses will be based on the safety analysis
population. Descriptive statistics will include means,
standard deviations, medians and ranges for continuous
variables (including changes), and frequency distributions
for discrete variables. Time-to-event data will be analysed
by Kaplan–Meier plots and appropriate event rates using
person-time “at risk” denominators will be given. Details of
the analyses to be performed will be described in the
statistical analysis plan.
4 Discussion
The ACT-ONE trial investigates a novel approach to the
therapy of cancer-related cachexia. The primary endpoint of
change in the rate of weight loss is clinically relevant, as
weight loss is both a defining feature of cachexia and a
major complaint of sufferers. Given the importance of loss
of lean tissue to the symptoms of cachexia including fatigue
and loss of functional capacity, it is highly plausible that a
reduction in the rate of further weight loss may be
associated with improvements in both symptoms and
objective functional capacity, measures of which have
therefore been incorporated as secondary efficacy assess-
ment endpoints in this study.
There have been very few trials of drug therapies to reduce
weight loss in cancer cachexia. The ACE inhibitor imidapril
has been trialled in 200 patients with one of three cancer types
and has been reported to have improved weight in two
(Colorectal and non-small cell lung cancer) but neither in the
third-type studied (pancreatic) nor in the pre-specified analysis
of all three cancer types taken together (http://www.biotech-
intelligence.com/html/html/2a462148882a297c8eafbeaf
baeff7ff.html). Ostarine, an investigational selective andro-
gen receptor modulator enhanced lean body mass and
muscle performance in a phase II clinical trial in patients
with cancer cachexia. Ostarine led to significant increase in
the primary endpoint of lean body mass (LBM) change with
an associated improvement in muscle performance measured
by stair climb in patients with cancer cachexia. The change
from baseline in LBM for the placebo, 1- and 3-mg treatment
groups was 0.1, 1.5 (p=0.001) and 1.3 kg (p=0.045),
respectively, at the end of the 16-week trial (http://www.
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pharmaceutical-business-review.com/news/gtxs_phaseii_can
cer_cachexia_trial_meets_primary_endpoint_090611). Inflix-
imab was studied in 89 patients with pancreatic cancer-
related cachexia and did not show a statistically significant
effect on lean body mass [13]. Etanercept (a dimeric fusion
protein inhibitor of TNF) was tested in 63 evaluable patients
with cancer-related weight loss and achieved no significant
benefit in terms of weight gain or reduced weight loss [14].
In a phase II clinical study, the orally administered grehlin
agonist anamorelin was shown to produce an improvement in
total body mass and a trend towards increased lean mass over
a 12-week period in patients with cancer, but without any
improvement in quality of life [15]. Anamorelin is now being
examined in phase III clinical trials for patients with cachexia
due to non-small cell lung cancer.
Other ongoing phase II trials in cancer cachexia include
interventions such as the immunomodulator OHR/AVR118 in
30 cancer cachexia patients (http://www.marketwire.com/
press-release/ohr-pharmaceutical-enrolls-first-three-patients-
new-clinical-site-ongoing-phase-2b-cachexia-1368449.htm),
a pilot study of APD209 (an oral fixed-dose combination of
a progestin and a selective β2-agonist) in cancer cachexia in
16 patients (http://clinicaltrials.gov/show/NCT00895726)
and lenalidomide (an immunodulatory derivate of thalido-
mide) in 60 patients with cancer cachexia (http://clinical
trials.gov/ct2/show/NCT01127386?term=cachexia&rank=1).
Cachexia, despite being very common in many solid
tumour cancers, remains a poorly studied, under-diagnosed
and largely untreated complication that causes severe
symptomatic limitation and predisposes to in increased
mortality. The ACT-ONE trial will help evaluate the
potential role of an interesting approach to its management.
The ACT-ONE trial is part of a programme to evaluate the
role of MT-102 in cancer cachexia. Participants in ACT-ONE
who complete the 16-week treatment period still taking
randomised double-blind trial medication will be offered the
opportunity to join the ACT-TWO trial. The ACT-TWO trial
will continue the same randomised treatment allocations for
the period up to that last patient in ACT-ONE having
completed all investigations of the ACT-ONE trial and the
16-week period of trial medication. The ACT-TWO trial will
be the subject of a separate protocol and design paper and will
be separately powered with a different primary endpoint,
which will include observations made during the period of
double-blind therapy of ACT-ONE as well as the period of
double-blind trial medication in ACT-TWO.
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